AACE (@TheAACE) header
AACE (@TheAACE) profile picture

Official Twitter account for the American Association of Clinical Endocrinology (AACE). Elevating endocrinology since 1991. Retweets ≠ endorsements.

Jacksonville, FL
Joined May 2009
Photo by AACE (@TheAACE)Photo by AACE (@TheAACE)Photo by AACE (@TheAACE)Photo by AACE (@TheAACE)Photo by AACE (@TheAACE)Photo by AACE (@TheAACE)Photo by AACE (@TheAACE)Photo by AACE (@TheAACE)Photo by AACE (@TheAACE)Photo by AACE (@TheAACE)
Endocrine University starts today! @TheAACE Excited about this educational series, with adrenal lectures featuring expert speakers. I've always been a big fan of EU! @WashUMedEndo
2
2
10
711
Continuous methimazole for 60+ months showed <20% relapse rate compared to ~50% for standard 12-18 month courses, plus faster TSH normalization, more euthyroid time, fewer orbitopathy flares, and minimal late adverse events.👇🏻
Endocrine Practice Highlight: Long-Term Antithyroid Drug Therapy in the Management of Graves’ Hyperthyroidism: An Updated Narrative Review Findings showed that patient priorities, efficacy and safety, and higher remission rates could be achieved with long-term (more than) 5 years of antithyroid drug treatment, as compared to other treatment modalities. Read more: endocrinepractice.org/articl… @vtangpricha
2
3
176
How @GoogleResearch is using wearable data and AI to predict metabolic risk. I did this interview with @aametwally1, metabolic researcher at Google few weeks ago and now we have insulin resistance prediction in @GooglePixel_US Google pixel watch! @TheAACE @AACEMENA @TheEndoSociety @EndocrineToday @AmDiabetesAssn #diabetes aaceendocrine.ai/videos/news…
2
3
228
Our paper on the clinical spectrum of #parathyroidcarcinoma is out in AACE Endocrinology and Diabetes! It was a real team effort. Grateful to our coauthors (@Jessicaabramo) and everyone who contributed, and of course editors at @TheAACE (@vtangpricha) sciencedirect.com/science/ar…
4
13
769
Can physicians create models without writing code? Agentic - no code thyroid nodule risk stratification from ultrasound images. Our latest paper @TheEndoSociety JCEM #Thyroid #EndoTwitter #MedTwitter We used @huggingface ML-Intern to create this model. This democratize model creation. @abidlabs @TheAACE @AmThyroidAssn @ClementDelangue see paper at academic.oup.com/jcem/advanc…
1
4
1
5
562
As Chair of the AACE Awards Committee, I invite you to nominate a deserving colleague for an @TheAACE Award. Help us recognize the outstanding clinicians, educators, researchers, and leaders who make a difference in endocrinology every day. #WeAreAACE pro.aace.com/about/aace-awar…
1
4
12
1,350
Dyslipidemia management is an important part of comprehensive diabetes care and cardiovascular risk reduction.
Dyslipidemia is a major driver of cardiovascular risk in patients with type 2 diabetes (T2D), and lipid management is a key component of the the latest AACE Consensus Statement: Algorithm for Management of Adults with Type 2 Diabetes - 2026 Update. Immediate Past President Scott D. Isaacs, MD, FACP, FACE, reviews new recommendations on LDL-C goals and individualized care in this population. Listen to the podcast at reachmd.com/programs/heart-m…. #WeAreAACE
2
6
1,257
🚀 New @TheAACE diabetes technology consensus: 🔹 #CGM for most people with diabetes 🔹 #AID regardless of diabetes type or C-peptide 🔹 Connected pens for MDI 🔹 Workflows, equity & hospital continuation 🚀 #Diabetes tech is expanding. 👇🏻🔗
2
17
43
2,100
GLP1 receptor agonists, especially #semaglutide, followed by liraglutide & exenatide have excellent safety in people with end stage renal (ESRD) disease on renal replacement therapy. On an average 7kg weight loss,3kg/m2 reduction in BMI following 1 year therapy with semaglutide in ESRD Weight loss with GLP1RAs in obese people with ESRD is associated with better outcomes following renal transplant endocrinepractice.org/articl… @NephJC @renal_TD @nkf @TheAACE @CVKidneyCare @rssdi @icmr
3
9
1
31
1,834
Practice changing implications in paediatric endocrinology Aromatase Inhibitors (AI) with Growth Hormone (GH) combination therapy is the best treatment option for improving height outcomes in adolescent boys with short stature (SS) and advanced Bone Age (BA) AI+GH is superior to the currently considered standard treatment [GnRHa (goserelin/leuprolide)+GH] Best AI to use is Letrozole followed by Anastrazole Cost of 3month therapy of Letrozole 2.5mg/day ( INR 2,100/ USD 22) Cost of 3 month therapy of GnRHa (Goserelin 10.8mg) (INR 28,000/ USD 295) GnRHa= Gonadotropin receptor agonist endocrinepractice.org/articl… @TheAACE @AmerAcadPeds @JAMAPediatrics @CanPaedSociety @pesk_kenya @PedEndoDiabMet @PEndocrinology @ped_endo @adolescenteando @adhdghana @acamh @1adoIescente @IndiaESI @CMEINDIA1 @paedendo @growthhormoneuk @shortstatureegy @SSSS_Org @kunalmahajan4 @abm_kamrul @JenaSweekruti
4
10
1
36
2,400
Our latest invited review in Endocrine Practice about application of AI in thyroidology. It was great working with @GonzaloDiazSoto . #AI #Thyroid @TheAACE sciencedirect.com/science/ar…
1
8
22
1,346
New @TheAACE guidance on managing dyslipidemia in type 2 diabetes is here. In this Heart Matters podcast, I discuss what has changed, including LDL goals, cardiovascular risk reduction, and how to individualize lipid management for our patients with T2D. reachmd.com/programs/heart-m…
2
7
27
1,396
The bridge to affordable obesity care opens today, July 1. Help your Medicare patients access life-changing treatments for a flat $50 monthly copay. Learn the specific administrative workflows and clinical eligibility rules today using OCAN’s provider resources in the comments link.
1
3
2
178
Replying to @TheAACE
#Endo2026 Scott Issacs speaking in MAFLD @TheEndoSociety excellent overview..:::: @aace past president
1
1
393
Congratulations to Dr. Sina Jasim on earning the FACE (Fellow of the American Association of Clinical Endocrinology) designation and on her appointment to @TheAACE Board of Directors. These distinguished honors reflect her leadership, expertise, and dedication to the field.
2
1
6
504
ARE YOU READY? 🚦 On July 1, the landscape of obesity care will change significantly with the launch of the @CMSGov GLP-1 Bridge program. @ObesityAdvocacy @AmDiabetesAssn @ObesityAction @OMAsocial @ASMBS and @ObesitySociety are hosting a critical conversation for patients and clinical teams on how to navigate this new model before launch day. You can make the difference. Have the conversation with patients, families and caregivers. Join us! 🗓️June 18 ⏰12 PM or 7 PM ET (Live Q&A) 🔗RSVP: obesitycareadvocacynetwork.c…
3
2
1
7
892
Just like a resident memorizing practice exams, an AI that memorizes training data will fail in the real world. In my latest for @TheAACE Endocrine AI, I explore overfitting, data leakage, and the critical skepticism clinicians need tinyurl.com/2s3z67vb @MayoClinicEndo
2
6
267
important for clinicians.
This article highlights that subclinical hypothyroidism is relatively common among patients with type 2 diabetes mellitus and that autoimmune thyroid markers, particularly anti-TPO antibodies, are more prevalent in this group compared to non-diabetic controls. Read more: endocrinologydiabetes.org/ar… @vtangpricha
1
2
225